Comparison of fluticasone furoate and fluticasone propionate for the treatment of Japanese cedar pollinosis

Allergy and Asthma Proceedings

Volumn 30, Issue 1, 2009, Pages 84-94

  Okubo, Kimihiro ^a   Nakashima, Mitsuyoshi ^b   Miyake, Noboru ^c   Komatsubara, Masaki ^c   Okuda, Minoru ^a,d  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Development and Medical Affairs Division   (Japan)

^d Japan Allergy and Asthma Clinic   (Japan)

Author keywords

Allergic rhinitis; Clinical trial; Corticosteroid; Fluticasone furoate; Fluticasone propionate; Intranasal, nasal spray; Placebo controlled; Safety; Steroid

Indexed keywords

FLUTICASONE FUROATE; FLUTICASONE PROPIONATE; NOSE SPRAY; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMMON COLD SYMPTOM; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIAGNOSTIC PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOSCOPY; EPISTAXIS; FEMALE; HEADACHE; HUMAN; JAPAN; JAPANESE CEDAR; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOSE CONGESTION; POLLEN ALLERGY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RHINORRHEA; RHINOSCOPY; SCORING SYSTEM; SNEEZING;

ADMINISTRATION, INTRANASAL; ADULT; AGED; ALLERGENS; ANDROSTADIENES; CRYPTOMERIA; DOUBLE-BLIND METHOD; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NASAL OBSTRUCTION; POLLEN; PRURITUS; RHINITIS, ALLERGIC, SEASONAL; SEVERITY OF ILLNESS INDEX; SNEEZING;

EID: 63449091573     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2009.30.3182     Document Type: Article

References (30)

1. Committee of Practical Guidance for Management of Allergic Rhinitis. Definition, diagnosis, and classification. In Practical Guideline for the Management of Allergic Rhinitis in Japan. Chap I. 5th ed. [in Japanese]. Tokyo: Life Science, 2005. 2-5.
2. Bousquet J, van Cauwenberge P, and Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 108:S147-S334, 2001.
3. van Cauwenberge P, Bachert C, Passalacqa G, et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergy and Clinical Immunology. Allergy 55:116-134, 2000.
4. Okuda M. Epidemiology of Japanese cedar pollinosis throughout Japan. Ann Allergy Asthma Immunol 91:288-296, 2003.
5. Baroody FM. Allergic rhinitis: Broader disease effects and implications for management. Otolaryngol Head Neck Surg 128:616-631, 2003.
6. Blaiss MS. Cognitive, social, and economic costs of allergic rhinitis. Allergy Asthma Proc 21:7-13, 2000.
7. Okuda M, Ohkubo K, Goto M, et al. Comparative study of two Japanese rhinoconjunctivitis quality-of-life questionnaires. Acta Otolaryngol 125:736-744, 2005.
8. Schoenwetter WF, Dupclay L Jr, Appajosyula S, et al. Economic impact and quality-of-life burden of allergic rhinitis. Curr Med Res Opin 20:305-317, 2004.
9. Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc 28:3-9, 2007.
10. Rosenwasser L. New insights into the pathophysiology of allergic rhinitis. Allergy Asthma Proc 28:10-15, 2007.
11. 2LEN and AllerGen. Available online at www.whiar.org/docs/ARIA-WR- wm.pdf; last accessed February 15, 2008.
12. Berger WE, Godfrey JW, and Slater AL. Intranasal corticosteroids: The development of a drug delivery device for fluticasone furoate as a potential step toward improved compliance. Expert Opin Drug Deliv 4:689-701, 2007.
13. Valotis A, and Högger P. Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate. Respir Res 8:54, 2007.
14. Sorbera LA, Serradell N, and Bolos J. Fluticasone furoate. Drugs Future 32:12-16, 2007.
15. Martin BG, Ratner PH, Hampel FC, et al. Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal allergic rhinitis in adults and adolescents. Allergy Asthma Proc 28:216-225, 2007.
16. Okuba K, Nakashima M, Miyaki N, et al. Dose-ranging study of fluticasone furoate nasal spray for Japanese patients with perennial allergic rhinitis. Curr Med Res Opin 24:3393-3403, 2008.
17. Fokkens WJ, Jogi R, Reinartz S, et al. Once daily fluticasone furoate nasal spray is effective in seasonal allergic rhinitis caused by grass pollen. Allergy 62:1078-1084, 2007.
18. Kaiser HB, Naclerio RM, Given J, et al. Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 119:1430-1437, 2007.
19. Nathan RA, Berger W, Yang W, et al. Effect of once-daily fluticasone furoate nasal spray on nasal symptoms in adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 100:497-505, 2008.
20. Vasar M, Houle PA, Douglass JA, et al. Fluticasone furoate nasal spray: Effective monotherapy for symptoms of perennial allergic rhinitis in adults/adolescents. Allergy Asthma Proc 29:313-321, 2008.
21. Rosenblut A, Bardin PG, Muller B, et al. Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis. Allergy 62:1071-1077, 2007.
22. Okuda M. Nasal provocation testing. In Rhinitis. Settipane GA (Ed). Providence: OceanSide Publications, 325-334, 1991.
23. Okuda M, Miura I, Juji F, et al. A novel method of counting eosinophils in nasal secretion of allergic rhinitis by hemocyto-metric method. Int Arch Allergy Immunol 104(suppl 1):6-8, 1994.
24. Okuda M. Grading the severity of allergic rhinitis for treatment strategy and drug study purposes. Curr Allergy Asthma Rep 1:235-241, 2001.
25. Weiner JM, Abramson MJ, and Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: Systematic review of randomised controlled trials. BMJ 317:1624-1629, 1998.
26. Price D, Bond C, Bouchard J, et al. International Primary Care Respiratory Group (IPCRG) Guidelines: Management of allergic rhinitis. Prim Care Respir J 15:58-70, 2006.
27. Blaiss MS. Safety considerations of intranasal corticosteroids for the treatment of allergic rhinitis. Allergy Asthma Proc 28:145-152, 2007.
28. Allen A, Down G, Newlands A, et al. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects. Clin Ther 29:1415-1420, 2007.
29. Patel D, Ratner P, Clements D, et al. Lack of effect on adult and adolescent hypothalamic-pituitary-adrenal axis function with use of fluticasone furoate nasal spray. Ann Allergy Asthma Immunol 100:490-496, 2008.
30. Meltzer EO, Stahlman JE, Leflein J, et al. Preferences of adult patients with allergic rhinitis for the sensory attributes of fluticasone furoate versus fluticasone propionate nasal sprays: A randomized, multicenter, double-blind, single-dose, crossover study. Clin Ther 30:271-279, 2008.